Enhancement of Antibody-dependent Cell-mediated Cytotoxicity by Endowing IgG with FcαRI (CD89) Binding

Overview

Journal MAbs

Specialty Allergy & Immunology

Date 2015 May 14

PMID 25970007

Citations 37

Authors

M Jack Borrok

Nadia M Luheshi

Nurten Beyaz

Gareth C Davies

James W Legg

Herren Wu

William F DallAcqua

Ping Tsui

Affiliations

Soon will be listed here.

Abstract

Fc effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP) are crucial to the efficacy of many antibody therapeutics. In addition to IgG, antibodies of the IgA isotype can also promote cell killing through engagement of myeloid lineage cells via interactions between the IgA-Fc and FcαRI (CD89). Herein, we describe a unique, tandem IgG1/IgA2 antibody format in the context of a trastuzumab variable domain that exhibits enhanced ADCC and ADCP capabilities. The IgG1/IgA2 tandem Fc format retains IgG1 FcγR binding as well as FcRn-mediated serum persistence, yet is augmented with myeloid cell-mediated effector functions via FcαRI/IgA Fc interactions. In this work, we demonstrate anti-human epidermal growth factor receptor-2 antibodies with the unique tandem IgG1/IgA2 Fc can better recruit and engage cytotoxic polymorphonuclear (PMN) cells than either the parental IgG1 or IgA2. Pharmacokinetics of IgG1/IgA2 in BALB/c mice are similar to the parental IgG, and far surpass the poor serum persistence of IgA2. The IgG1/IgA2 format is expressed at similar levels and with similar thermal stability to IgG1, and can be purified via standard protein A chromatography. The tandem IgG1/IgA2 format could potentially augment IgG-based immunotherapeutics with enhanced PMN-mediated cytotoxicity while avoiding many of the problems associated with developing IgAs.

Citing Articles

Engineering of anticancer human immunoglobulin A equipped with albumin for enhanced plasma half-life.

Mester S, Chan C, Lustig M, Foss S, Jansen J, Leangen Herigstad M PNAS Nexus. 2025; 4(2):pgaf042.

PMID: 40041621 PMC: 11878800. DOI: 10.1093/pnasnexus/pgaf042.

Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review).

Hou R, Wu X, Wang C, Fan H, Zhang Y, Wu H Int J Oncol. 2025; 66(4).

PMID: 40017131 PMC: 11900975. DOI: 10.3892/ijo.2025.5734.

With great power, comes great responsibility: the importance of broadly measuring Fc-mediated effector function early in the antibody development process.

Crescioli S, Jatiani S, Moise L MAbs. 2025; 17(1):2453515.

PMID: 39819511 PMC: 11810086. DOI: 10.1080/19420862.2025.2453515.

Immunoglobulin A Antibodies: From Protection to Harmful Roles.

Gleeson P, Camara N, Launay P, Lehuen A, Monteiro R Immunol Rev. 2024; 328(1):171-191.

PMID: 39578936 PMC: 11659943. DOI: 10.1111/imr.13424.

Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases.

Rolin C, Zimmer J, Seguin-Devaux C Cell Mol Immunol. 2024; 21(7):643-661.

PMID: 38789528 PMC: 11214628. DOI: 10.1038/s41423-024-01176-4.

References

Valerius T, Stockmeyer B, van Spriel A, Graziano R, Repp R, Deo Y . FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood. 1997; 90(11):4485-92. View

Mattu T, Pleass R, Willis A, Kilian M, Wormald M, Lellouch A . The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fcα receptor interactions. J Biol Chem. 1998; 273(4):2260-72. DOI: 10.1074/jbc.273.4.2260. View

Umana P, Jean-Mairet J, Moudry R, Amstutz H, Bailey J . Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol. 1999; 17(2):176-80. DOI: 10.1038/6179. View

van Egmond M, Hanneke van Vuuren A, van de Winkel J . The human Fc receptor for IgA (Fc alpha RI, CD89) on transgenic peritoneal macrophages triggers phagocytosis and tumor cell lysis. Immunol Lett. 1999; 68(1):83-7. DOI: 10.1016/s0165-2478(99)00034-6. View

Iannello A, Ahmad A . Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies. Cancer Metastasis Rev. 2006; 24(4):487-99. DOI: 10.1007/s10555-005-6192-2. View

Snoeck V, Peters I, Cox E . The IgA system: a comparison of structure and function in different species. Vet Res. 2006; 37(3):455-67. DOI: 10.1051/vetres:2006010. View

Satoh M, Iida S, Shitara K . Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin Biol Ther. 2006; 6(11):1161-73. DOI: 10.1517/14712598.6.11.1161. View

Dechant M, Beyer T, Schneider-Merck T, Weisner W, Peipp M, van de Winkel J . Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor. J Immunol. 2007; 179(5):2936-43. DOI: 10.4049/jimmunol.179.5.2936. View

van Egmond M . Neutrophils in antibody-based immunotherapy of cancer. Expert Opin Biol Ther. 2007; 8(1):83-94. DOI: 10.1517/14712598.8.1.83. View

10.

Richards J, Karki S, Lazar G, Chen H, Dang W, Desjarlais J . Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther. 2008; 7(8):2517-27. DOI: 10.1158/1535-7163.MCT-08-0201. View

11.

Bruckheimer E, Fazenbaker C, Gallagher S, Mulgrew K, Fuhrmann S, Coffman K . Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia. 2009; 11(6):509-17, 2 p following 517. PMC: 2685440. DOI: 10.1593/neo.81578. View

12.

Strohl W . Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol. 2009; 20(6):685-91. DOI: 10.1016/j.copbio.2009.10.011. View

13.

van der Steen L, Tuk C, Bakema J, Kooij G, Reijerkerk A, Vidarsson G . Immunoglobulin A: Fc(alpha)RI interactions induce neutrophil migration through release of leukotriene B4. Gastroenterology. 2009; 137(6):2018-29.e1-3. DOI: 10.1053/j.gastro.2009.06.047. View

14.

Weiner L, Surana R, Wang S . Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010; 10(5):317-27. PMC: 3508064. DOI: 10.1038/nri2744. View

15.

Balu S, Reljic R, Lewis M, Pleass R, McIntosh R, van Kooten C . A novel human IgA monoclonal antibody protects against tuberculosis. J Immunol. 2011; 186(5):3113-9. PMC: 3115510. DOI: 10.4049/jimmunol.1003189. View

16.

Souto J, Vila L, Bru A . Polymorphonuclear neutrophils and cancer: intense and sustained neutrophilia as a treatment against solid tumors. Med Res Rev. 2009; 31(3):311-63. DOI: 10.1002/med.20185. View

17.

Moore G, Chen H, Karki S, Lazar G . Engineered Fc variant antibodies with enhanced ability to recruit complement and mediate effector functions. MAbs. 2010; 2(2):181-9. PMC: 2840237. DOI: 10.4161/mabs.2.2.11158. View

18.

Lohse S, Brunke C, Derer S, Peipp M, Boross P, Kellner C . Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages. J Biol Chem. 2012; 287(30):25139-50. PMC: 3408157. DOI: 10.1074/jbc.M112.353060. View

19.

Jung S, Kelton W, Kang T, Ng D, Andersen J, Sandlie I . Effective phagocytosis of low Her2 tumor cell lines with engineered, aglycosylated IgG displaying high FcγRIIa affinity and selectivity. ACS Chem Biol. 2012; 8(2):368-75. DOI: 10.1021/cb300455f. View

20.

Boross P, Lohse S, Nederend M, Jansen J, van Tetering G, Dechant M . IgA EGFR antibodies mediate tumour killing in vivo. EMBO Mol Med. 2013; 5(8):1213-26. PMC: 3944462. DOI: 10.1002/emmm.201201929. View